Engineering pathways for integrating functional Cas9 protein into OMVs
Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.
VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source.